The RMI group has completed sertain projects

Print 31 May 2023

The RMI Group has exited from the capital of portfolio companies Marinus Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc. is engaged in the development and marketing of anti-seisure medicines in various forms of release, mainly to combat epilepsy. In 2022-2023 The company has registered in the US and EU and brought to market Ztalmy^(R) - the first drug specifically intended for the treatment of seizures in children caused by a rare (orphan) disease - Childhood Desintegrative Disorder (CDD) caused by a mutation in the CDKL5 gene. Details: https://marinuspharma.com/

Syndax Pharmaceuticals, Inc. completes clinical trials and is about to launch in the market new oncology drugs for treatment of “liquid” cancers, such as acute forms of leukemia and multiple line lymphomas. The company has achieved impressive results of treatment through multi-year clinical research programs. Details: https://syndax.com/

Atea Pharmaceuticals, Inc. conducts clinical research in the area of combating RNA viruses. Main researches are being carried out to fight against the new coronavirus infection covid-19 and the hepatitis C virus. Details: https://ateapharma.com/

Return